Wu San-Gang, Wang Yan, Zhou Juan, Sun Jia-Yuan, Li Feng-Yan, Lin Huan-Xin, He Zhen-Yu
Xiamen City Cancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Xiamen University Xiamen, People's Republic of China.
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Collaborative Innovation Center of Cancer Medicine Guangzhou, People's Republic of China.
Am J Cancer Res. 2015 Jan 15;5(2):844-53. eCollection 2015.
This study aimed to investigate the prognostic value of the number of involved lymph nodes (pN), number of removed lymph nodes (RLNs), lymph node ratio (LNR), number of negative lymph nodes (NLNs), and log odds of positive lymph nodes (LODDS) in breast cancer patients. The records of 2,515 breast cancer patients who received a mastectomy or breast-conserving surgery were retrospectively reviewed. The log-rank test was used to compare survival curves, and Cox regression analysis was performed to identify prognostic factors. The median follow-up time was 64.2 months, and the 8-year disease-free survival (DFS) and overall survival (OS) were 74.6% and 82.3%, respectively. Univariate analysis showed that pN stage, LNR, number of RLNs, and number of NLNs were significant prognostic factors for DFS and OS (all, P < 0.05). LODDS was a significant prognostic factor for OS (P = 0.021). Multivariate analysis indicated that pN stage and the number of NLNs were independent prognostic factors for DFS and OS. A higher number of NLNs was associated with higher DFS and OS, and a higher number of involved lymph nodes were associated with poorer DFS and OS. Patients with a NLNs count > 9 had better survival (P < 0.001). Subgroup analysis showed that the NLNs count had a prognostic value in patients with different pT stages and different lymph node status (log-rank P < 0.05). For breast cancer, pN stage and NLNs count have a better prognostic value compared to the RLNs count, LNR, and LODDS. Number of negative lymph nodes should be considered for incorporation into staging for breast cancer.
本研究旨在探讨乳腺癌患者受累淋巴结数量(pN)、切除淋巴结数量(RLNs)、淋巴结比率(LNR)、阴性淋巴结数量(NLNs)以及阳性淋巴结对数比值(LODDS)的预后价值。回顾性分析了2515例行乳房切除术或保乳手术的乳腺癌患者的记录。采用对数秩检验比较生存曲线,并进行Cox回归分析以确定预后因素。中位随访时间为64.2个月,8年无病生存率(DFS)和总生存率(OS)分别为74.6%和82.3%。单因素分析显示,pN分期、LNR、RLNs数量和NLNs数量是DFS和OS的显著预后因素(均P<0.05)。LODDS是OS的显著预后因素(P=0.021)。多因素分析表明,pN分期和NLNs数量是DFS和OS的独立预后因素。NLNs数量越多与DFS和OS越高相关,受累淋巴结数量越多与DFS和OS越差相关。NLNs计数>9的患者生存率更高(P<0.001)。亚组分析显示,NLNs计数在不同pT分期和不同淋巴结状态的患者中具有预后价值(对数秩P<0.05)。对于乳腺癌,与RLNs计数、LNR和LODDS相比,pN分期和NLNs计数具有更好的预后价值。应考虑将阴性淋巴结数量纳入乳腺癌分期。